Can pelvic exercises boost estrogen therapy for bladder control?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with stress urinary incontinence. * Women who have been naturally postmenopausal for at least 1 year or are postmenopausal due to bilateral oophorectomy (surgical removal of both ovaries). * Have had sexual intercourse to ensure feasibility of urogenital tract examination and assessment. * Patients who consent to participate in the study and comply with the treatment protocol, including performing pelvic floor muscle training (PFMT) and completing topical vaginal estrogen therapy. Exclusion Criteria: * Patients with concomitant neurological disorders, urinary tract infections, prior pelvic radiotherapy, or congenital malformations of the lower urinary tract. * Genitourinary malformations or fistulas causing continuous urinary incontinence. * Genitourinary cancers or tumors of the urinary tract. * History of spinal cord injury or central nervous system injury affecting the centers that control urination. * Patients previously treated for stress urinary incontinence (SUI) (surgery, medications, exercises). * Patients with severe heart disease, coronary artery disease, or myocardial ischemia. * Patients with pelvic organ prolapse stage III or higher, unexplained vaginal bleeding, confirmed or suspected breast cancer, or vaginitis. * Presence of premalignant factors or suspected steroid-dependent cancers such as endometrial carcinoma. * History of or current hepatic tumors, or progressive liver or biliary disease. * Coagulation/thrombotic disorders, or a history of thromboembolism or stroke. * Severe hypertriglyceridemia. * Hypersensitivity to any component of vaginally administered estrogen products. * The patient or family members are unable to use a smartphone (Android or iOS) to participate in the monitoring program. * The patient does not agree to participate in the study.